Tianjin Chase Sun PharmaceuticalLtd Management
Management criteria checks 3/4
Tianjin Chase Sun PharmaceuticalLtd's CEO is Dan Zheng, appointed in Mar 2017, has a tenure of 7.75 years. directly owns 0.05% of the company’s shares, worth CN¥5.67M. The average tenure of the management team and the board of directors is 7.8 years and 5.3 years respectively.
Key information
Dan Zheng
Chief executive officer
CN¥2.6m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.05% |
| Management average tenure | 7.8yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly
Nov 22
We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings
Nov 01Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects
Sep 26These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well
Aug 02There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Jun 12Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03
May 22This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts
May 21Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04CEO
Dan Zheng (60 yo)
7.8yrs
Tenure
CN¥2,608,700
Compensation
Ms. Dan Zheng serves as General Manager of Tianjin Chase Sun Pharmaceutical Co.,Ltd since March 24, 2017 and serves as its Vice Chairman since April 24, 2019. She serves as Director of Tianjin Chase Sun Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman | 7.8yrs | CN¥2.61m | 0.050% CN¥ 5.7m | |
| Executive GM | 13yrs | CN¥1.81m | 0.050% CN¥ 5.7m | |
| Deputy GM | no data | CN¥979.30k | no data | |
| Deputy GM | no data | CN¥1.11m | 0.022% CN¥ 2.6m | |
| GM of Human Resource Center & Deputy GM | no data | CN¥1.21m | 0.023% CN¥ 2.6m | |
| Deputy General Manager | 7.8yrs | CN¥1.32m | 0.031% CN¥ 3.6m | |
| Deputy General Manager | 2.7yrs | CN¥1.76m | no data | |
| Secretary of the Board of Directors | 1.8yrs | no data | no data |
7.8yrs
Average Tenure
48.5yo
Average Age
Experienced Management: 300026's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman | 7.7yrs | CN¥2.61m | 0.050% CN¥ 5.7m | |
| Executive GM | 5.7yrs | CN¥1.81m | 0.050% CN¥ 5.7m | |
| Deputy GM | 5.7yrs | CN¥979.30k | no data | |
| Deputy GM | less than a year | CN¥1.11m | 0.022% CN¥ 2.6m | |
| Chairman | 24.3yrs | CN¥2.66m | 10.24% CN¥ 1.2b | |
| Independent Director | 4.9yrs | CN¥120.00k | no data | |
| Employee Representative Member of Supervisory Board & Securities Affairs Representative | 11.7yrs | CN¥91.00k | no data | |
| Independent Director | 7yrs | CN¥120.00k | no data | |
| Independent Director | 4.9yrs | CN¥120.00k | no data | |
| Independent Director | 4.1yrs | CN¥120.00k | no data | |
| Director | less than a year | no data | no data | |
| Director | 1.4yrs | no data | no data |
5.3yrs
Average Tenure
55yo
Average Age
Experienced Board: 300026's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin Chase Sun Pharmaceutical Co.,Ltd is covered by 19 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |